Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Z

Selected  z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clini

Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely ea

/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to

Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weight

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinic

Relay had its initial public offering in 2020. The company's lead therapy is being tested for the tr

U.S. stocks were lower on Thursday, with Nasdaq falling over 200 points. Advance Auto Parts Inc (NYS

CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clini

This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and

Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalie

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinic

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with

Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink va

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowes

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share versus the Zacks C

FDA Breakthrough Therapy designation granted to  zovegalisib for PIK3CA-mutant, HR+/HER2- advanced b

Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely

Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

  During Thursday's session, 406 companies made new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Tuesday's session, 275 companies made new 52-week lows.

  On Thursday, 283 companies set new 52-week lows.

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea

  On Friday, 199 companies reached new 52-week lows.

  Thursday's session saw 189 companies set new 52-week lows.

  During Wednesday's session, 117 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

  On Tuesday, 91 stocks hit new 52-week lows.

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnin

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the co

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin

  Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for

  On Tuesday, 951 companies hit new 52-week lows.